Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with risk for thromboembolic complications and mortality in patients with COVID-19
Authors: S Luo, B Samelko, J M Du-Fay-De-Lavallaz, J M D Gomez, A M Zemke, T Suboc, K A Williams, S Fugar, J A Simmons, A S Volgman, S Hayek, J Reiser